.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Daiichi Sankyo
Colorcon
Argus Health
Moodys
Cantor Fitzgerald
US Army
Deloitte
Federal Trade Commission
McKesson

Generated: September 23, 2017

DrugPatentWatch Database Preview

HORIZANT Drug Profile

« Back to Dashboard

Which patents cover Horizant, and when can generic versions of Horizant launch?

Horizant is a drug marketed by Arbor Pharms Llc and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and forty-two patent family members in twenty-five countries.

The generic ingredient in HORIZANT is gabapentin enacarbil. There are twenty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the gabapentin enacarbil profile page.

Summary for Tradename: HORIZANT

Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list24
Clinical Trials: see list9
Patent Applications: see list74
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:HORIZANT at DailyMed

Pharmacology for Tradename: HORIZANT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-001Apr 6, 2011RXYesYes► Subscribe► Subscribe► Subscribe
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo► Subscribe► Subscribe ► Subscribe
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-001Apr 6, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-001Apr 6, 2011RXYesYes► Subscribe► Subscribe ► Subscribe
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-001Apr 6, 2011RXYesYes► Subscribe► Subscribe ► Subscribe
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: HORIZANT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,833,140 Orally administered dosage forms of GABA analog prodrugs having reduced toxicity► Subscribe
7,423,169Methods for synthesis of acyloxyalkyl derivatives of GABA analogs► Subscribe
8,906,412GABA analog prodrug sustained release oral dosage forms► Subscribe
7,232,924Methods for synthesis of acyloxyalkyl derivatives of GABA analogs► Subscribe
7,186,855Prodrugs of GABA analogs, compositions and uses thereof► Subscribe
9,150,503Crystalline form of .gamma.-aminobutyric acid analog► Subscribe
8,367,722Methods of using prodrugs of pregabalin► Subscribe
9,238,616Prodrugs of gaba analogs, compositions and uses thereof► Subscribe
6,972,341 Prodrugs of GABA analogs, compositions and uses thereof► Subscribe
8,168,623Prodrugs of GABA analogs, compositions and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: HORIZANT

Country Document Number Estimated Expiration
Japan2008518971► Subscribe
Japan5001227► Subscribe
Australia2002345664► Subscribe
European Patent Office1677812► Subscribe
Israel174600► Subscribe
Norway20062112► Subscribe
Japan2004534057► Subscribe
New Zealand567711► Subscribe
Australia2003247522► Subscribe
Hong Kong1083018► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Dow
Accenture
Colorcon
Federal Trade Commission
UBS
Chubb
Cipla
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot